Back to Results

A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease

Interested in this Trial?

Contact Us

Trial Status Terminated

Trial Identifier

NCT02221362

Condition

Late-onset Pompe Patients Untreated or Treated With rhGAA

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

Study 701-901, a multicenter, multinational, longitudinal, non-interventional observational study in subjects, at least 18 years old, diagnosed with late-onset Pompe disease prospectively collects data to understand clinical progression in terms of respiratory function, symptomology, genotype, biochemistry, endurance and selected subject-reported measures for 24 weeks followed by a 240 week additional observation period for up to 100 subjects.

Eligibility Criteria

Birth Sex

All

Age

From 18 Years

Healthy Volunteers

No

Study Type:

Observational

Number of Participants:

30

Study Started:

2014-12

Study Updated:

2016-10-31

Trial Locations

  • Westmead Hospital, Dept. of Genetic Medicine

    Westmead, New South Wales, Australia

  • Women's and Children's Hospital

    Adelaide, South Australia, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Porto Alegre, , Brazil

  • Recife, , Brazil

  • Ribeirao Preto, , Brazil

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • Alexandroupolis, , Greece

  • Athens, , Greece

  • Larissa, , Greece

  • Thessalonika, , Greece

  • St. Vincent's University Hospital

    Dublin, , Ireland

  • Seoul National University Hospital

    Seoul, , Korea, Republic of

  • Copernicus, St. Adalbert Hospital

    Gdansk, , Poland

  • Diamond Clinic

    Krakow, , Poland

  • Insitute of Psychiatry and Neurology

    Warsaw, , Poland

  • Spitalul Clinic Judetean de Urgenta "Sf. Apostol Andrei"

    Constanta, , Romania

  • Belgrade, , Serbia

  • National University Hospital

    Singapore, , Singapore

  • Ljubljana, , Slovenia

  • Hospital de la Santa Creu I Sant Pau

    Barcelona, , Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, , Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, , Spain

  • Mackay Memorial Hospital

    Taipei, , Taiwan

Inclusion Criteria

  • Willing and able to provide written informed consent after the nature of the study has been explained and prior to any study-related procedure
  • Diagnosed with late-onset Pompe disease based on current or previous genomic testing and/or endogenous GAA activity
  • At least 18 years of age at study entry
  • Willing and able to comply with all study procedures

Exclusion Criteria

  • Requires non-invasive ventilatory support while awake and in the upright position
  • Concurrent disease, medical condition, or extenuating circumstance that, in the opinion of the investigator, might compromise study completion or data collection
  • Unable to perform baseline efficacy assessment

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us